Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147911 | 0.78 | GRIN2D (0.33) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL11113985 | 0.76 | HTT (0.32) | TRPA1 | |
| SCHEMBL3145397 | 0.74 | GRIN2D (0.33) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL28134606 | 0.74 | TSHR (0.33) | GRIN2BTRPA1 | |
| SCHEMBL28134604 | 0.74 | TSHR (0.33) | GRIN2BTRPA1 | |
| SCHEMBL3155159 | 0.74 | GRIN2D (0.33) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL31016265 | 0.74 | GRIN2D (0.33) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL3136547 | 0.74 | GRIN2D (0.33) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL3163944 | 0.74 | GRIN2D (0.33) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6637475 | 0.73 | GRIN2D (0.32) | GRIN2DGRIN3BADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035306-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20110282045-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-7947824-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090286971-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7528247-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1412369-B1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20050033043-A1 | Reacting a blocked 2-deoxy-alpha-D-arabinofuranosyl halide with the potassium salt of an adenine derivative to form 2-deoxy-beta-D-adenine nucleosides stereoselectively; use making antiviral or anticancer agents | GENZYME CORPORATION | 2005-02-10 | — | — | US | disclosed |
| EP-1412369-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | Ilex Oncology, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6680382-B2 | COUPLING ADENINE DERIVATIVE WITH BLOCKED ARABINOFURANOSYL DERIVATIVE TO FORM 2-CHLORO-9-(2'-DEOXY-2'-FLUORO-B-ARABINOFURANOSYL)ADENINE; ANTICANCER AGENTS; VIRICIDES | ILEX PRODUCTS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030114663-A1 | Process for preparing purine nucleosides | GENZYME CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003011877-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033043-A1 | Reacting a blocked 2-deoxy-alpha-D-arabinofuranosyl halide with the potassium salt of an adenine derivative to form 2-deoxy-beta-D-adenine nucleosides stereoselectively; use making antiviral or anticancer agents | SAMHD1, DCTD, DUT | GRIN2D 1134/4885GRIN3B 2316/4885ADRA1D 604/4885 |
| US-20130035306-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | SAMHD1, APRT, DCTD | GRIN2D 2952/4885GRIN3B 3596/4885ADRA1D 1581/4885 |
| US-20030114663-A1 | Process for preparing purine nucleosides | SAMHD1, APRT, NUDT1 | GRIN2D 3136/4885GRIN3B 3413/4885ADRA1D 2845/4885 |
| US-20110282045-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | PNP, SAMHD1, NUDT1 | GRIN2D 1925/4885GRIN3B 3131/4885ADRA1D 1044/4885 |
| US-20090286971-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | PNP, SAMHD1, NUDT1 | GRIN2D 1925/4885GRIN3B 3131/4885ADRA1D 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.